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A bstract
B inding o f viruses to  cell surface m olecules is  
an essentia l step in  v iral in fection . In  v itro  
s tudies suggested that the αvβ3 in tegrin  receptor 
is  the epithelia l cell receptor for H antaan  virus  
(H TN V). W hether β3 is  in  vivo  the only or central 
cellular receptor for HTNV infection is not know n. 
To  investigate the ro le  o f β3 in tegrin  for cellu lar 
entry of H TN V, w e established an HTNV infection  
m odel in  new born m urine pups. In fected pups  
d ied  at an  average age of 14.2 ± 1.1 days w ith  
high levels of viral antigen detected in their brain, 
lung, and kidney. Pre-injection of blocking m ono -
clonal antibod ies (m A b) specific  for either β3 o r 
αv pro longed survival s ignificantly  to  a  m axim al 
average survival o f 19.7  ± 1.5 days (P ＜ 0.01) 
and 18.4 ± 0.9 days (P ＜ 0.01), respectively. XT- 
199, a chem ical b locker of the αvβ3 receptor also  
prolonged survival to 19.5 ± 1.3 days (P ＜ 0.01). 
In  contrast to  these receptor b lockades, anti- 
H TN V antibody w as not on ly  ab le  to  pro long  
survival, but 20%  of infected pups achieved long- 
term  survival. A n anti-m urine β1 antibody com pa-
ratively pro longed survival (19.0 ± 1.2 days), 
suggesting that HTNV infection is partly m ediated  
through integrin  β1 receptors as w ell as through  
β3 receptors in  vivo . O ur data dem onstrate  that 
the β3 receptor is im portant for H TN V infection  
in  vivo , but a lso suggest that H TN V m ay utilize  
add itional receptors beyond β3 for cellu lar entry  
w ith in  an  organism .
K eyw ords: Hantaan virus; integrin β3; integrin β1; 
receptor; viral entry
In troduction
Hantaviruses are a genus of genetically- and serologi-
cally-related viruses belonging to the family Bunyaviri-
dae. This family includes the etiologic agents of two 
distinct disease syndromes in humans, hemorrhagic 
fever with renal syndrome (HFRS) and hantavirus pul-
monary syndrome (HPS), which are transmitted from 
rodents to humans (Lee et al., 1978; Nichol et al., 
1993). Old World hantanviruses, such as the Hantaan 
(HTN) (Asia), Seoul (worldwide), Dobrava (Europe), 
Puumala (Scandinavia and western Russia), and re-
lated viruses cause HFRS, which is characterized by 
fever, renal failure, thrombocytopenia and in severe 
cases, hemorrhagic manifestations. New World han-
taviruses, Sin Nombre, Andes and related viruses 
(North and South America), cause HPS, which is 
characterized by severe acute respiratory dystunction 
and a mortality rate of approximately 50% (Nicole et 
al., 1993; Song et al., 1994; Lopez et al., 1996).
  Cellular receptor binding is the first step in viral 
infection. Many different cell surface molecules can 
serve as receptors for the attachment or entry of vi-
ruses. One commonly used receptor family utilized for 
viral entry is the integrin. Viruses that utilize these 
receptors include echoviruses 1, 8, 9, and 22 (Bergel-
son et al., 1992; Bergelson et al., 1993; Pulli et al., 
1997; Nelsen-Salz et al., 1999), coxackievirus A9 (Roi-
vainen et al., 1994), foot-and mouse disease virus 
(FMDV) (Jackson et al., 1997; Jackson et al., 2000), 
papillomavirus (Evander et al., 1997), adenovirus (Wick-
ham et al., 1993), adeno-associated virus type 2 (Sum-
merford et al., 1999), and rotavirus (Coulson et al., 1997).
  Recent data have demonstrated that integrins con-
taining the β3 chain may also be involved in the 
cellular entry of hantavirus (Gavrilovskaya et al., 
1998; 1999). However, to date, there is no strong 
evidence to indicate that this mechanism of cellular 
entry of hantavirus is of biological relevance in vivo. 
In the present studies, we establish a newborn murine 
model for HTN virus (HTNV) infection and show that 
β3-containing integrins play a part in efficient HTNV 
infection in this model.
In vivo characterization of the integrin β3 as a receptor for
Hantaan virus cellular entry
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M ateria ls and M ethods
Virus  
HTNV (strain 76-118) and Prospect Hill virus (PHV, 
strain 405), were propagated in Vero E6 cells (WT, 
Vero C1008; ATCC CRL 1586 USA), maintained in 
Dulbecco's modified Eagle's medium supplemented 
with 5% heat-inactivated fetal bovine serum (FBS), 2 
mM L-glutamine, and antibiotics (100 µg/L gentamycin) 
(Life Technologies, Inc.) at 37oC, 5% CO2 incubator. 
Quantitative virus titers were measured by counting 
plaques on Vero E6 cell monolayers, as previously 
described (White et al., 1982). For animal inoculation, 
dilutions of virus stock (1.5×107 PFU) were made in 
phosphate buffered salaine (PBS, pH 7.4, Life Tech-
nologies, Inc.) containing a final concentration of 
0.75% bovine albumin and stored in aliquots at -80oC 
until used.
M urine H TN  survival stud ies
A previous study demonstrated that newborn labora-
tory mice were susceptible to infection with HTNV, 
and the mortality by HTNV was age-dependent and 
with an inoculum 10 LD50, was 100% in mice in-
fected within 72 h of birth (Kim and McKee, 1985). 
Therefore, animal manipulations with HTNV under this 
study were performed using newborn mice less than 
24 h after birth (Day 1), and as a control, mice 3 
days after birth (Day 3). Outbred ICR pregnant mice 
were obtained to produce newborn mice (Sam Tako 
Inc., Korea). To evaluate the effects of blocking anti-
bodies, newborn mice were injected intraperitoneally 
(i.p.) with a hamster anti-mouse integrin β3 (CD61) 
chain-specific antibody, hamster anti-mouse integrin 
αv (CD 51) chain-specific antibody or hamster anti- 
mouse integrin β1 (CD29) chain-specific antibody 
(PharMingen,) or 50 µl of an mouse anti-HTNV sera 
prepared as previously described (Lee et al., 1985) 
or LM609 (Chemicon), a murine anti-human αvβ3 
monoclonal antibody that does not cross-react with 
the murine vitronectin receptor (Cheresh, 1987). 
Following adoptive transfer of antibodies of 5-40 µg 
(2.8-22.8 mg/kg body weight), the mice were chal-
lenged 16-18 h later by i.p. injection of 2,000 PFU 
of HTNV, strain 76-118. Additional newborn pups 
were pre-treated instead with a small-molecule, non-
peptide-selective αvβ3-receptor antagonist XT-199 [3- 
(3-(3-(4, 5-dihydroimidazol 2-ylamino) propyloxyliso-
xazol-5-yl) carbonylamino)-2-(phenylsulfonylamino) pro-
pionic acid, DuPont Pharmaceuticals Co.]. These 
pups received i.p. 5 mg/kg of XT-199 on the day 
before viral infection followed by 10 mg/kg of the 
antagonist for an additional 14 days. For all groups, 
survival rates were recorded for 5 weeks after 
challenge. Each set of HTNV challenges were per-
formed on groups of 10 cohorted pups and were 
performed two or three times for each group. The 
results shown are the mean of each experiment. All 
animals were treated according to the Laboratory 
Institute Animal Control Guideline in compliance with 
National Institutes of Health-American Association of 
Laboratory Animal Control Guidelines. All the animal 
experiments were done in a BSL3 facility. 
Indirect im m unofluorescence assay (IFA )
For these studies, mice were sacrificed at 3- to 4- 
day intervals from days 4 to 35 (n = 2 per time point 
per group) after viral infection. Organs were excised 
aseptically and frozen at -70oC until examined. Blood 
samples were collected at the same time. For de-
tection of HTNV antigen in tissues, specimens were 
embedded in a polyethylene glycol compound 
(Tissue-Tek II, Miles Laboratories). Sections were cut 
at 4 µm in a CryoCut II (Ames Cryostat microtome) 
at 25oC and fixed in cold acetone. Prepared slides 
were incubated with anti-HTNV mouse hyperimmune 
ascitic fluid, then stained for indirect immunofluore-
scence with fluorescein isothiocyanate (FITC)-labeled 
goat antimouse IgG (1:32 diluted, ICN/Cappel). Slides 
were examined with a Carl Zeiss-standard microscope 
with epifluorescence and FITC filter system (×400, 
50W, Leitz Co.). IFA for blood samples was per-
formed using HTNV infected Vero E6 cells as the 
antigen (Jung et al., 2004). The IFA titers were ex-
pressed as the reciprocal of the highest dilution of 
the antisera that resulted in a specific immunofluore-
scence in the cytoplasm of the infected cells.
Statistical analysis
The Student's T test was use to assess the signifi-
cance of the mean time of survival. Studies were 
done on 10 animals tested in two to three separate 
analyses.
R esu lts and D iscuss ion
Establishing  a new born pup m odel for H TN V
infection
For control studies, newborn mice pups less than one 
day old (Day 1) were injected with 500 PFU to 7,500 
PFU HTNV per recipient. Viral doses ≥ 2,000 PFU 
significantly decreased mice survival (Figure 1A), with 
accompanying body weight reduction by day 12-14 
after infection (data not shown). In contrast, ino-
culations with less than 1,500 PFU had minimal ef-
fects on survival. Mice survival was -60% at Day 14 
using an innoculum of 2,000 PFU. Accordingly, 2,000 
PFU per pup HTNV recipient dose was chosen for 
the in vivo experiment as partial efficacy of receptor 
blocking might be appreciated by longer survival.
  This model depends on the age of the pups at the 
time of HTNV infection. Inoculation with 2,000 PFU 
HTNV, even after only three days after birth (Day 3), 
did not significantly increase mortality over no HTNV 
inoculation controls, with an 80% survival rate (Figure 
1B). However, use of a viral dose of 5,000 PFU in 
Day 3 mice decreased survival to 20% at 12-14 days 
(Figure 1B). These findings suggest that the mice de-
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velop a protective immune mechanism by three days 
of age and that the studies for the importance of the 
αvβ3 receptor on HTNV infection would need to be 
carried out on Day 1 mice. 
  The distribution of viral antigen in target organs, 
such as brain, lung and kidney, and the anti-HTN 
antibody titered in blood were determined in the Day 
1 and Day 3 animals infused with 2,000 PFU (Table 
1). After inoculation with HTNV on Day 1, viral 
antigen was detectable as early as Day 4 at low con-
centrations. Viral antigen levels peaked at a modest 
titer (≥ 64) on Day 14 in most tissues rapidly followed 
by the demise of the pups. These pups never de-
veloped a high titer of anti-HTNV antibody. In the 
Day 3 mice, none of the animals developed de-
tectable HTNV in their tissues, but did develop high 
antibody titers (≥2,048), which peaked at Day 28. 
The modest immune response in Day 1 animals may 
explain the susceptibility of these animals to HTNV 
infection.
In  vivo HTN infection blocking studies w ith anti-αv 
and anti-β3 antibodies
The use of antibodies to block viral binding to a spec-
ific receptor has been used successfully to identify 
receptors important in viral uptake (Greve et al., 
1989). Antibodies to β3 integrins and the high affinity 
β3 integrin ligand, vitronectin, block in vitro infection 
by pathogenic hantaviruses, but not to non-pathogenic 
hantaviruses. It suggested that integrin-specific in-
teractions could contribute to hantavirus diseases 
(Gavrilovskaya et al., 1998; 1999). Thus, CHO cell 
lines expressing recombinant αIIbβ3 or αvβ3 integrins, 
dramatically enhanced the infectivity of HTNV of this 
cell line. Pretreatment of CHO cell lines with antisera 
to β3 integrins specifically reduced the number of cells 
infected by HTNV by ＞ 90%. We, therefore, explored 
whether such antibodies would affect the course of 
HTNV infection in our newborn pup model and 
provide new insights into its in vivo pathobiology.
  Figure 2 shows the inhibitory effect on viral toxicity 
of an i.p. infusion of the anti-mouse αv antibody pre-
ceding infection. Mice survival rate was not appreci-
ably different after injections at the two lowest doses 
of 1-2 µg (0.6-1.1 mg/kg body weight) (data not 
shown), but was extended in the ≥ 5 µg (2.8-22.8 
mg/kg body weight) treatment group. The effect peak-
ed at 20 µg (11.4 mg/kg body weight) anti-αv antibody 
per pup compared to animals infused with PBS alone
Figure 1. Percent survival rate of HTNV infected mice. Day 1 mice (10 per group) were intraperitoneally injected with (A) 1,000 ( △ ), 1,500 ( ▲ ),
2,000 ( □ ), 2,500 ( ■ ) and 5,000 PFU ( ▽ ) HTNV, respectively. Controls (-) were injected with PBS only without virus ( ○ ). (B) Day 3 mice
( △ ) or Day 5 mice injected with 5,000 PFU ( ▲ ). Controls (-) ( ○ ) were injected with PBS only without virus, and controls (+) ( ● ) were injected
with 2,000 PFU of HTNV. The survival rates of HTNV infected mice were calculated daily, and the experiment was terminated on days 35. Each symbol
shows mean survival value. 
T a b le  1 . Distribution of HTN viral antigen in tissue and development
of antibodies in blood. ICR mice were infected intraperitoneally with
40 µ l of virus (2000 PFU). Two mice from each infected group were
killed on Days 7, 14, 21, 28, or 35 after infection for IFA test.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
IFA titer in
                 ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Days (p.i.)  Group Organ
                 ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ Blood
Brain Lung Kidney
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Day 7 Day 1 - + + ＜16
Day 3 - - - ＜16
Day 14 Day 1 +++ +++ ++ ≥64
Day 3 - - - ＜16
Day 21 Day 3 - - - 2048
Day 28 Day 3 - + - 4096
Day 35 Day 3 - + - 2048
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Antigen scoring: 0, no positive cells; 1+, rare positive cells; 2+, few
positive cells; 3+, moderate number of positive cells; 4+, many positive
cells.
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Figure 3. Percent survival rate of HTNV infected mice with anti-murine 
β3 antibody. Mice (10 mice per group, Day 1) were intraperitoneally 
injected with 2000 PFU of HTNV, after treatment of mAb-β3 at 
concentrations of 5 ( △ ), 10 ( ▲ ), 20 (  □ ), and 40( ■ ) µg. Controls
(-) ( ○ ) were not injected with HTNV, and controls (+) ( ● ) were injected
with 2000 PFU of HTNV, but no antibody. The survival rates of HTNV
infected mice were calculated daily, and the experiment was terminated
on Day 35. Each symbol shows mean survival value.
Figure 2. Percent survival rate of HTNV infected mice with mAb-αv. Day
1 mice (10 per group) were intraperitoneally injected with 2000 PFU of
HTNV, after treatment of mAb-αv at concentrations of 5 ( △ ), 10 ( ▲ ),
20 ( □ ), and 40 ( ■ ) µg. Controls (-) ( ○ ) were not injected with
HTN, and controls (+) ( ● ) were injected with 2000 PFU of HTNV, but
no antibody. The survival rates of HTNV infected mice were calculated 
daily, and the experiment was terminated on Day 35. Each symbol shows
mean survival value.
Figure 4. Percent survival rate of HTNV infected mice under various 
conditions. Mice (10 mice per group, Day 1) were studied as follows: 
(A) Controls (-) ( ○ ) were not injected with HTN, and controls (+)
( ● ) were injected with 2000 PFU of HTNV, but no antibody. Animals 
were injected with HTNV after treatment of combinations of antibodies 
at concentrations of [each 10 µg of α v and β 3 ( △ ), each 20 µg of 
α v and β 3 ( ▲ )], (B) Controls (-) ( ○ ) were not injected with HTNV, 
and controls (+) ( ● ) were injected with 2000 PFU of HTNV, but no 
antibody. Animals were injected with HTNV while being treated with 
XT-199( ▲ ). (C) Controls (-) ( ○ ) were not injected with HTNV, and 
controls (+) ( ● ) were injected with 2000 PFU of HTNV, but no antibody. 
Animals were injected with HTNV after treatment with anti-HTNV sera 
[anti-HTNV ( △ )] or LM609 ( ▲ ). The survival rates of HTNV infected 
mice were calculated daily, and the experiment was terminated on day 
35. Each symbol shows mean survival value.
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(survival: 18.4 ± 0.9 days vs. 14.2 ± 1.1 days, re-
spectively, P ＜ 0.01) or to animals infused with 
LM609, a murine anti-human αvβ3 mAb that does not 
react with murine αvβ3 (Cheresh, 1987) (survival: 18.4
± 0.9 days vs. 14.0 ± 0.9 days, respectively, P＜
0.01).
  An anti-murine β3 antibody was used in similar 
mice survival studies (Figure 3). At the lowest doses 
of 1 and 2 µg (0.6-1.1 mg/kg body weight) of antibody 
injected per pup, survival was nearly indistinguishable 
from that of pups injected with PBS (data not shown). 
However at higher antibody doses, pups survived for 
a longer period of time after HTNV infection, although 
all treated mice still succumbed by Day 23. This 
attenuation of the death rate was maximal at 10 µg 
(5.7 mg/kg body weight) of the anti-CD61 β3 antibody 
per pup (survival: 19.7 ± 1.5 days vs. 14.2 ± 1.1 
days, respectively, P＜ 0.01). 
  There is no murine integrin αvβ3 complex-specific 
antibody currently available. To further examine the 
significance of the integrin αvβ3 for HTN viral 
infectivity, combined treatment with the anti-mouse av 
and anti-mouse β3 antibodies was tested (Figure 4A). 
We anticipated that combined therapy would have a 
synergistic or at least an additive protective effect. 
Neither was seen. At two different doses of the two 
antibodies, survival was prolonged for several days 
compared to control animals, but no difference was 
noted compared to treatment with the individual anti-
bodies. 
  It is evident that antibody does not inhibit the virus 
entry in a dose dependent manner. An important 
finding of our studies is that in the presence of high 
concentration of antibodies, blocking of HTNV binding 
and infection by antibodies was relatively inefficient 
(Figure 3 and 4A). This may be because antibody 
have unexpected side effects by steric hinderance of 
other ligand-receptor interactions or only partial 
inhibition of the integrin signaling.
  Histological samples were also examined. No dif-
ference in tissue histology for HTN viral infection was 
seen for the Day 1 mice for any of the blocking 
studies (data not shown). Additionally, there was no 
difference in the anti-HTNV titers that developed (data 
not shown). We, therefore, could not correlate the 
observed improvement in survival with the animals 
mounting a significant immune response.
B locking the αvβ3 receptor using XT-199
The observations of a limited improvement in survival 
using the above anti-αv and anti-β3 blocking anti-
bodies suggest that HTN viral infection is more com-
plex than simply cell entry using the αvβ3 receptor and 
that one can achieve a significant, but limited, in-
terruption in HTNV infection by blocking the αvβ3 
receptor in the infectious process in newborn pups. 
This conclusion is supported by additional studies 
using a specific αvβ3-integrin receptor inhibitor XT-199 
at its known blocking dose (Bishop et al., 2001). In 
these studies, XT-199 was begun prior to HTNV 
infection and given for 14 days. These treated pups 
showed a significant improvement in survival rate 
compared to controls (Figure 4B) that was com-
parable to the improvement in survival seen with the 
blocking antibody studies (Figure 4A). 
A bility  o f H TN  antibody against H TN  in fection
Our data in Table 1 suggest that by Day 3 of life, 
murine pups are protected from HTN infection. These 
animals coincidentally develop high titers of anti- 
HTNV antibodies. We wondered whether it is these 
antibodies that are the critical difference between Day 
1 and Day 3 pups in our HTNV infection model and 
whether the limited ability of antibodies to murine αvβ3 
to protect animals may be secondary to viral infection 
by other mechanisms. We, therefore, i.p. injected anti- 
HTNV antibody on Day 1 of life prior to HTN infection 
with 2,000 PFU using an anti-HTNV titer ≥2,048 
(Figure 4C). Anti-HTNV sera not only prolonged the 
overall survival rate from controls (27.0 ± 2.7 days 
vs. 14.2 ± 1.1 days, respectively, P＜ 0.01), it also 
resulted in the survival of 20% of the animals. 
Although mortality was still high, no survivors were 
ever seen in any tested animals using αv or β3 re-
ceptor blocking antibodies or drug. 
  These studies suggest that a major part of the 
reason why Day 3 mice may be protected from HTNV 
infection may indeed be their ability to mount a rapid 
and vigorous anti-viral antibody response. These data 
show that an antibody approach can be protective 
against death in this model. However, the inability of 
antibodies and drugs directed at the vitronectin re-
ceptor to fully protect offsprings from HTNV-related 
death suggest that this virus may have an alternative 
mechanism of cell entry during in vivo infection.
Figure 5. Percent survival rate of HTNV or PHV infected mice with 
anti-murine β1 antibody. Mice (10 mice per group, Day 1) were 
intraperitoneally injected with 2000 PFU of HTNV or PHV, after treatment
of mAb-β1 at concentrations of 10 ( □ ), 2 ( ■ ) µg with HTNV, and
10 ( ▲ ) µg with PHV. Controls (-) ( ○ ) were not injected with viruses,
and controls (+) were injected with 2000 PFU of HTNV ( ● ) or PHV
( △ ). The survival rates of HTNV infected mice were calculated daily, 
and the experiment was terminated on Day 35. Each symbol shows mean
survival value.
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  Such similar cases of partial inhibition have been 
known. Adenovirus papillomavirus, FMDV, or coxsac-
kievirus are the examples. Anti-integrin antibodies 
alone can not bring about complete inhibition of 
cellular entry into these organisms. These viruses, 
which also enter cells via αvβ3 integrins, have been 
reported to use additional cell surface receptors 
(Wickham et al., 1993; Roivainen et al., 1994; Huang 
et al., 1996; Evander et al., 1997; Neff et al., 1998). 
Other viruses have been reported to utilize multiple 
RGD-dependent integrins to initiate infection (Trian-
tafilou et al., 2001). RGD ligand motifs recognized by 
αvβ3 and αIIbβ3 integrins are absent from all hantavirus 
proteins. Like that of rotaviruses, their entry is not 
blocked by RGD peptides, indicating that their in-
teraction with the β3 chain is independent of the 
integrin binding to physiologic ligands (Gavrilovskaya 
et al., 1999; Guerrero et al., 2000). Certainly, similar 
HTNV infection studies using the described β3null 
mouse (Hodivala-Dilke et al., 1999) would further 
support our model, but these animals are presently 
not available. Furthermore, because of their bleeding 
diathesis may be problematic for doing i.p. injections.
Possibility  of o ther in tegrins involved in  H TN V
infection
We, therefore, were interested in testing other recep-
tors, focusing on related integrins. The in vitro obser-
vations that the nonpathogenic PHV cellular entry is 
associated with β1 integrin (Gavrilovskaya et al., 
1999), suggest that HTNV infection might be able to 
use other integrins for cell entry in vivo. We tested 
the possibility of whether β1 integrins may be involved 
in HTNV infection. An anti-murine β1 antibody was 
used in mice survival studies against HTNV or PHV 
infection (Figure 5). At doses of 10 and 20 µg 
(5.7-11.4 mg/kg body weight) of antibody injected per 
pup, survival in Day 1 mice after standard HTNV 
infection was maximal (18.5 ± 1.1 days and 19.0 ±
1.2 days, respectively, P＜ 0.01). Days of survival 
rate at 20 µg of the anti-β1 antibody per pup was 
significantly prolonged compared to animals infused 
with PBS alone (19.0 ± 1.2 days vs. 15.0 ± 1.4 
days, respectively, P＜ 0.01). The prolongation of 
survival after anti-β1 antibodies suggest that HTNV 
infection is partly mediated through integrin β1 
receptors as well as through β3 receptors in vivo. 
  In summary, these studies indicate that hantavi-
ruses clearly utilize the αvβ3 receptor for viral entry 
in vivo. These studies also suggest that this may not 
be the only mechanism by which hantaviruses enter 
cells in a living organism. Our data would, therefore, 
predict that blocking strategies directed against the 
αvβ3 receptor in the clinical care of HTNV infections 
may not be as efficacious as therapy directed against 
the HTN virion itself. Our data also suggest that β1 
intergrins are another family of receptors through 
which HTNV can enter cells in vivo. Combined studies 
show that the blockade of β1 and β3 is not synergistic 
(data not shown). Collectively, these data will contri-
bute substantially to precise pathogenetic approach 
toward understanding the mechanism of virulence.
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